Made With Uberflip Content Marketing

BIO-Europe Spring 2017

The process of bringing a pharmaceutical drug to market once a lead compound has been identified: from drug discovery, funding, clinical trials, FDA approvals, and partnerships

  • Barcelona biotech companies shine light on regional entrepreneurship

    Barcelona biotech companies shine light on regional entrepreneurship

    Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies....

    Read
  • Increase the value of your asset: Think with the end in mind

    Increase the value of your asset: Think with the end in mind

    Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The Target Product Profile is like a postcard of your desired destination. It informs the data...

    Read
  • What’s the deal with Immuno-oncology partnering?

    What’s the deal with Immuno-oncology partnering?

    Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...

    Read
  • Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona is an attractive location for business and trade, and has experienced a revival in the biopharma sector in recent years with the outsourcing of innovation from pharma companies to...

    Read
  • Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Guest article by BIOCAT, the Bioregion of Catalonia After the great success of previous editions (2010 and 2013), the Bioregion of Catalonia is again hosting BIO-Europe Spring® 2017 (March 20–22),...

    Read
  • BIO-Europe Spring® 2016: BeyondSpring Pharmaceuticals outlines Plinabulin plans8:15

    BIO-Europe Spring® 2016: BeyondSpring Pharmaceuticals outlines Plinabulin plans

    Watch Video
  • BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech9:04

    BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech

    Dr. Graham Lumsden, CEO of London-based biotech Motif Bio, a company focused on the development of therapeutics for infectious diseases, talks with Mike Ward, global director of content for Informa Ph

    Watch Video
  • BIO-Europe Spring® 2016: Purdue CEO outlines plans for growth away from opioid market12:39

    BIO-Europe Spring® 2016: Purdue CEO outlines plans for growth away from opioid market

    During the 2016 BIO-Europe Spring® partnering meeting in Stockholm, Sweden, Mark Timney, president and CEO of Purdue Pharma, caught up with Mike Ward, global director of content for Informa Pharma Int

    Watch Video
  • BIO-Europe® 2016: Immunotherapies: Partnership models driving cures1:04:18

    BIO-Europe® 2016: Immunotherapies: Partnership models driving cures

    While we have seen new immunotherapies enter the market and there are many exciting products in development; we have also seen recent setbacks. The field is risky and partnerships among biotechs, phar

    Watch Video
  • Partnering in the Pharma World: BIO-Europe® and industry trends 2012-2015

    Partnering in the Pharma World: BIO-Europe® and industry trends 2012-2015

    Read Flipbook
  • BIO-Europe Spring® 2016: How to get Takeda Ventures to notice your startup10:21

    BIO-Europe Spring® 2016: How to get Takeda Ventures to notice your startup

    Dr. Ilan Zipkin, senior investment director at Takeda Ventures, talks with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about what the venture capital fi

    Watch Video
  • Drug pricing scandal rocks the USA but does not shake European systems

    Drug pricing scandal rocks the USA but does not shake European systems

    Single-payer European healthcare systems may hold a stronger position to defend the value of drugs than the fragmented payer system in the United States, according to a blue-ribbon panel of...

    Read
  • BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?9:27

    BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?

    Dr. Thomas Zioncheck, senior director of Genentech Partnering (a unit of Roche subsidiary Genentech Inc.), speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights po

    Watch Video
  • BIO-Europe Spring® 2016: AZ BioVenture Hub CEO says aim is an innovative ecosystem12:46

    BIO-Europe Spring® 2016: AZ BioVenture Hub CEO says aim is an innovative ecosystem

    AstraZeneca’s BioVentureHub CEO Magnus Björsne tells Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about the exchange's intention to generate a climate of

    Watch Video
  • Biotechs scramble as public markets dry up, but can private equity help?

    Biotechs scramble as public markets dry up, but can private equity help?

    Does the slump in the IPO boom create a bigger pool of private capital to invest in drug development, or do emerging companies have their backs to the wall? Professional investors hold mixed...

    Read
  • BIO-Europe® 2016 recap from day one

    BIO-Europe® 2016 recap from day one

    It was the best of times, it was the worst of times. This was the biotech industry in 2016. While this year marked yet another blockbuster year for dealmaking where larger pharma companies scooped...

    Read
  • BIO-Europe® 2016- Value and the pricing of innovation1:08:53

    BIO-Europe® 2016- Value and the pricing of innovation

    Balancing the cost of innovation and ensuring access to high-quality, effective medical treatment continues to be a challenge for all modern healthcare systems. Significant shifts in global and local

    Watch Video
  • Steps for choosing the right development partner

    Steps for choosing the right development partner

    Guest post by Laura Marquis, Vice President and Global Head, Emerging Biopharma, QuintilesIMS™ As I prepare for BIO-Europe® in Cologne, I’m excited by the tremendous opportunities for emerging...

    Read
  • Covance: Expedited drug development with a new programmatic model

    Covance: Expedited drug development with a new programmatic model

    Drug development is undergoing a major transformation in order to align with the new norma—replacing a transactional or just-in-time approach with strategic programmatic outsourcing. This new,...

    Read
  • Aging R&D takes center stage at BIO-Europe®

    Aging R&D takes center stage at BIO-Europe®

    Guest post by John Carroll, Co-Founder and Editor of Endpoints   Last spring I was fascinated to read a story about seniors lobbying to get into a study that was being created to examine the...

    Read
  • loading
    Loading More...